Results 111 to 120 of about 189,087 (191)

The need for a pragmatic, individualized treat-and-extend (T&E) treatment paradigm for centre-involving diabetic macular oedema. [PDF]

Eye (Lond), 2023
Chaudhary V, Retina Evidence and Trials INternational Alliance (R.E.T.I.N.A.) Study Group.   +1 more
europepmc   +1 more source

Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen. [PDF]

BMC Ophthalmol
Plasencia C, Eschle J, Hatz K.
europepmc   +1 more source

Aflibercept for Wet Age-Related Macular Degeneration: A Prospective, Randomized Trial Comparing Treat-And-Extend and Fixed Bimonthly Dosing. [PDF]

J Clin Med
Wu KY, Qian SY, Camiré A, Kim DT, Giunta M.   +4 more
europepmc   +1 more source

Predictors of treatment outcomes following treat-and-extend regimen with aflibercept for branch retinal vein occlusion: post-hoc analysis of the PLATON trial. [PDF]

Sci Rep, 2023
Son W, Jeong WJ, Park JM, Kim JY, Ji YS, Sagong M.   +5 more
europepmc   +1 more source

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. [PDF]

Eye (Lond)
Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, Lawrence D, Holz FG.   +6 more
europepmc   +1 more source

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. [PDF]

Sci Rep, 2023
Matsumoto H, Hoshino J, Nakamura K, Akiyama H.   +3 more
europepmc   +1 more source

Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration. [PDF]

Clin Ophthalmol
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH.   +11 more
europepmc   +1 more source

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration. [PDF]

BMC Ophthalmol
Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK.   +4 more
europepmc   +1 more source

Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. [PDF]

Sci Rep, 2022
Kim JH, Kim JW, Kim CG.
europepmc   +1 more source

Five-year Outcome of Aflibercept Administration with “Treat and Extend” for Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Iori Wada,1,2 Yuji Oshima,3 Yosuke Fukuda,1 Satomi Shiose,1 Kumiko Kano,1 Keijiro Ishikawa,1 Shintaro Nakao,4 Yoshihiro Kaizu,1,5 Eiichi Hasegawa,1,2 Ram Kannan,6,7 Tatsuro Ishibashi,1 Koh-Hei Sonoda1 1Department of Ophthalmology, Graduate School of ...
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH   +11 more
doaj